Abstract
Diosmetin (Dios), a flavone aglycone, is a major active ingredient of many herbal medicines. Previous studies implicated that the potential antitumor activities of Dios are mediated through multiple cell signaling pathways, however more investigations are required to reveal the targets and mechanisms of Dios. In this study, our results demonstrated that cell cycle progression and proliferation of HepG2 cells were inhibited by Dios. Meanwhile, Dios-induced liver cancer cell apoptosis was related with the p53 activation. After PFT-α, a p53 inhibitor was added into Dios-treated HepG2 cells, cell growth inhibition was partially reversed. These findings defined and supported that p53 is a novel target of Dios. By activating p53, Dios exerts anticancer effects by inducing cell cycle arrest and apoptosis in HepG2 cells.
Keywords: Diosmetin, HepG2, P53, apoptosis, flavonoids, ERK and JNK phosphorylation.
Protein & Peptide Letters
Title:Diosmetin, a Potential p53 Activator, Performs Anticancer Effect by Regulating Cell Cycling and Cell Proliferation in HepG2 Cells
Volume: 24 Issue: 5
Author(s): Bin Liu*, Miaomiao Zhang, Shuna Liu, Jie Ying, Jingjing Zhang, Hiroshi Kurihara, Weiqiang Zheng, Rong-Rong He*Runzhi Zhu
Affiliation:
- Infection department of Internal Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, Guangdong Province,China
- College of Pharmacy, Jinan University, Guangzhou 510632, Guangdong Province,China
Keywords: Diosmetin, HepG2, P53, apoptosis, flavonoids, ERK and JNK phosphorylation.
Abstract: Diosmetin (Dios), a flavone aglycone, is a major active ingredient of many herbal medicines. Previous studies implicated that the potential antitumor activities of Dios are mediated through multiple cell signaling pathways, however more investigations are required to reveal the targets and mechanisms of Dios. In this study, our results demonstrated that cell cycle progression and proliferation of HepG2 cells were inhibited by Dios. Meanwhile, Dios-induced liver cancer cell apoptosis was related with the p53 activation. After PFT-α, a p53 inhibitor was added into Dios-treated HepG2 cells, cell growth inhibition was partially reversed. These findings defined and supported that p53 is a novel target of Dios. By activating p53, Dios exerts anticancer effects by inducing cell cycle arrest and apoptosis in HepG2 cells.
Export Options
About this article
Cite this article as:
Liu Bin*, Zhang Miaomiao, Liu Shuna, Ying Jie, Zhang Jingjing, Kurihara Hiroshi, Zheng Weiqiang, He Rong-Rong*, Zhu Runzhi, Diosmetin, a Potential p53 Activator, Performs Anticancer Effect by Regulating Cell Cycling and Cell Proliferation in HepG2 Cells, Protein & Peptide Letters 2017; 24 (5) . https://dx.doi.org/10.2174/0929866524666170223094634
DOI https://dx.doi.org/10.2174/0929866524666170223094634 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Natural Products as a Source of Protein Kinase Activators and Inhibitors
Current Topics in Medicinal Chemistry Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Pharmacological and Clinical Studies on Purine Nucleoside Analogs- New Anticancer Agents
Mini-Reviews in Medicinal Chemistry Role of Stem Cells in Normal Liver and Cancer
Anti-Cancer Agents in Medicinal Chemistry HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design
Current Pharmaceutical Design Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science HSV-1 Based Amplicon Vectors as an Alternative System for the Expression of Functional HCV Proteins
Current Gene Therapy New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Herbal Phytochemicals as Immunomodulators
Current Immunology Reviews (Discontinued) Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Follicular Immunology Environment and the Influence on In Vitro Fertilization Outcome
Current Women`s Health Reviews Cytotoxic Activity of Polysubstituted 7-chloro-4-quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Fighting Tumor Cell Survival: Advances in the Design and Evaluation of Pim Inhibitors
Current Medicinal Chemistry Molecular Determinants of Gastrointestinal and Liver Cancers: Role of Bile Acid Activated Nuclear Receptors
Current Topics in Medicinal Chemistry Efficient Purification of rhG-CSF and its PEGylated Forms and Evaluation for In Vitro Activities
Protein & Peptide Letters